A Journal of the Gesellschaft Deutscher Chemiker

Angewandte Chemie

GDCh

International Edition

www.angewandte.org

Accepted Article

Title: Transformation of Receptor Tyrosine Kinases into Glutamate Receptors and Photoreceptors

Authors: Philipp Leippe, Johannes Broichhagen, Katia Cailliau, Alexandra Mougél, Marion Morel, Colette Dissous, Jérôme Vicogne, and Dirk Trauner

This manuscript has been accepted after peer review and appears as an Accepted Article online prior to editing, proofing, and formal publication of the final Version of Record (VoR). This work is currently citable by using the Digital Object Identifier (DOI) given below. The VoR will be published online in Early View as soon as possible and may be different to this Accepted Article as a result of editing. Readers should obtain the VoR from the journal website shown below when it is published to ensure accuracy of information. The authors are responsible for the content of this Accepted Article.

To be cited as: *Angew. Chem. Int. Ed.* 10.1002/anie.201915352
Angew. Chem. 10.1002/ange.201915352

Link to VoR: <http://dx.doi.org/10.1002/anie.201915352>
<http://dx.doi.org/10.1002/ange.201915352>

COMMUNICATION

Transformation of Receptor Tyrosine Kinases into Glutamate Receptors and Photoreceptors

Philipp Leippe,^{[a],[b],#} Johannes Broichhagen,^{[a],[b],#} Katia Cailliau,^[c] Alexandra Mougél,^[d] Marion Morel,^[e] Colette Dissous,^[d] Dirk Trauner*^{[a],[f]} and Jérôme Vicogne*^[d]

Abstract: Receptor tyrosine kinases (RTKs) are key regulators of cellular functions in metazoans. In vertebrates, RTKs are mostly activated by polypeptides but are not naturally sensitive to amino acids or light. Taking inspiration from Venus Kinase Receptors (VKRs), an atypical family of RTKs found in Nature, we have achieved the transformation of the human insulin (hIR) and hepatocyte growth factor receptor (hMET) into glutamate receptors by replacing their extracellular binding domains with the ligand-binding domain of metabotropic glutamate receptor type 2 (mGluR2). We then imparted light sensitivity by covalent attachment of a synthetic, glutamate-based photoswitch onto a self-labelling SNAP tag. Employing a *Xenopus laevis* oocyte kinase activity assay, we demonstrate how these chimeric RTKs, termed LihIR (Light-controlled human Insulin Receptor) and LihMET (Light-controlled human MET Receptor), can be used to exert optical control over insulin or MET signaling pathways. Our results outline a potentially general strategy to convert RTKs into photoreceptors.

Signal transduction is achieved by transmembrane proteins that undergo conformational changes upon extracellular ligand binding and activate intracellular signaling pathways or effect changes in transmembrane potential.^[1] These transmembrane proteins include ion channels, G protein-coupled receptors (GPCRs), and receptor-linked enzymes, such as receptor

tyrosine kinases (RTKs). In humans, 58 RTKs are encoded, comprising an important class of receptor-linked enzymes.^[2] They are involved in the control of critical cellular processes such as metabolism, differentiation, and the cell cycle, making them important targets in diabetes and cancer therapy.

A small and distinct class of RTKs is known as Venus Kinase Receptors (VKRs) (Fig. 1).^[3] Originally discovered in parasitic worms (e.g. *Schistosoma mansoni* (SmVKR)^[4]) and insects (e.g. in the honeybee *Apis mellifera* (AmVKR)^[5]), they are widespread in invertebrates but absent among vertebrates. These VKRs are activated by a variety of ligands, such as amino acids and ions^[3] and have recently received increased attention due to their involvement in gametogenesis and egg production in parasitic helminths^[6] as well as in pathogen vector mosquitoes.^[7] As such, they are novel drug targets for various infectious diseases. VKRs are named after their extracellular Venus Flytrap-like ligand-binding domain (LBD). This domain, also called “clamshell” domain, belongs to a larger family of LBDs that consist of two lobes, which close around their ligand.^[8] Derived from prokaryotic periplasmic binding proteins, LBDs of this type have been incorporated in transporters, ion channels, and GPCRs in the course of evolution.^[9] Prominent eukaryotic examples include ionotropic receptors, such as AMPA receptors, and the eight metabotropic glutamate receptors found in the human genome.

- [a] Dr. Philipp Leippe, Dr. Johannes Broichhagen, Prof. Dr. Dirk Trauner
Department of Chemistry, Ludwig-Maximilians-Universität München, and Munich Center for Integrated Protein Science, Butenandtstrasse 5-13, 81377 München, Germany
- [b] Dr. Philipp Leippe, Dr. Johannes Broichhagen
Present address: Department of Chemical Biology, Max Planck Institute for Medical Research, Jahnstr. 29, 69120 Heidelberg, Germany
- [c] Dr. Katia Cailliau
CNRS UMR 8576, University of Lille, Villeneuve d'Ascq, France.
- [d] Alexandra Mougél, Dr. Colette Dissous, Dr. Jérôme Vicogne
Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIL - Center for Infection and Immunity of Lille, F-59000 Lille, France
E-mail: jerome.vicogne@ibl.cnrs.fr
- [e] Dr. Marion Morel
Department of Biochemistry and Molecular Biology, Boonshoft School of Medicine, Wright State University, Dayton, Ohio 45435.
- [f] Prof. Dr. Dirk Trauner
Department of Chemistry, Silver Center for Arts and Science, New York University, 100 Washington Square East, New York, NY 10003, USA
E-mail: dirktrauner@nyu.edu

Supporting information for this article is given via a link at the end of the document.

Figure 1. Proteins with Venus-Flytrap like or clamshell LBDs. Presumably originating from periplasmic binding proteins, the Venus-Flytrap domain (dark grey) has been found in all classes of transmembrane proteins, such as ion channels, GPCRs, receptor-linked enzymes such as tyrosine kinase, the latter is only found in invertebrates (white). Vertebrate RTKs (light grey) do not bear clamshell LBDs.

The diversity of receptors and ion channels can be further increased through engineering of both extracellular sensory domains and intracellular downstream signaling domains.^[10] For instance, the extracellular LBD of the human insulin receptor has

COMMUNICATION

been fused to kinase domains of other RTKs to turn on different signaling pathways^[11]. Chimeric GPCRs have been engineered that combine the photosensitivity of opsins with the signaling pathways of G_s or G_q coupled receptors (OptoXR)^[12]. All of these chimeras have been engineered from domains *within* a class of receptors, but inter-domain swapping between receptor classes has been reported as well. For example, extracellular antigen recognition domains can be fused to different intracellular signaling domains and expressed in T cells to obtain chimeric antigen receptor T cells (CAR-Ts)^[13], which show promise in cancer immunotherapy. Similarly, "Syn-notch" receptors bear an antigen recognition domain and signal through the Notch pathway^[14]. Lastly, a plethora of chimeric proteins have been engineered that combine fluorescent proteins with sensory domains and have been used to quantify endogenous small molecules.^[15] However, to the best of our knowledge, synthetic receptors have never been created by combining protein modules from GPCRs and RTKs.

We now report that it is possible to convert both the human insulin receptor (hIR) and the human hepatocyte growth factor receptor (hMET) into glutamate receptors. This was achieved by exchanging the extracellular LBDs of these RTKs with the Venus Flytrap domain of the GPCR mGluR2. Following this, we equipped the engineered receptors with a glutamate-based photoswitch,^[16] which led to two new synthetic photoreceptors termed LihIR and LihMET.

Design of our constructs

The human insulin receptor (hIR) and the human hepatocyte growth factor receptor (HGFR or hMET) are among the best-studied RTKs due to their prominent role in metabolic and regenerative diseases, as well as in cancer. We therefore chose their transmembrane (TM) and intracellular tyrosine kinase (TK) domains and merged them with the extracellular LBD and the cysteine-rich domain (CRD) of mGluR2. The stiff CRD was retained to serve as a lever and to juxtapose the intracellular TKs following LBD closure. mGluR2 forms constitutive dimers held together by a disulfide bond between the LBDs^[17], similar to hIR. In addition, a *N*-terminal HA-tag and a self-labelling protein tag (SNAP)^[18] was added to enable the eventual attachment of a photoswitch (see below). Both chimeras, termed LihIR and LihMET, were fully evaluated for their ability to initiate cellular tyrosine kinase signaling upon glutamate and light activation (full sequences including details on cloning are provided in the Supporting Information). The topology of our constructs and their activation by glutamate and after BGAG labelling using light, respectively, is schematically shown in Fig. 2

Figure 2. Design of the chimeric light-controllable glutamate receptors LihIR and LihMET. (A) Chemical Structure of the PORTL BGAG₈ and the freely diffusible analog AG₁₂. BG = benzylguanidine for bioconjugation, A = azobenzene as a photoswitch with Δ = glutamate head group. The index refers to the number of PEG units in the linker or side chain. (B) LihIR and LihMET comprise a SNAP-mGluR2(LBD+CRD)-RTK(TM+TK) construct. Kinase activity can be evoked by addition of glutamate (left) or by bioorthogonal labelling of the SNAP tag with BGAG₈ and subsequent illumination.

Biological Assays

Xenopus laevis frog oocytes represent an excellent model system to study kinase function as they express all required components for deciphering mammalian cell signaling pathways.^[19] In stage VI oocytes, activation of mitogen-activated protein kinase (MAPK) pathway by progesterone (PG) or by ectopic expression of RTKs triggers a cellular process called germinal vesicle breakdown (GVBD, described in detail in Fig. S1). This GVBD reports kinase activation and can be easily monitored through visual inspection (Fig. 3A). Therefore, we expressed LihIR and LihMET chimeras in oocytes by cRNA microinjection and, after 5 h, confirmed full-length expression of both chimeras by HA immunoprecipitation and their subsequent detection at ~160 kDa by western blotting (Fig. 3B). As anticipated, glutamate treatment was able to initiate intracellular phosphorylation of LihIR and LihMET, revealed by a phosphotyrosine-specific antibody (PY20), and furthermore by downstream phosphorylation of Akt and ERK2 correlated with positive GVBD. Viability and correct maturation of the oocyte batch were confirmed using progesterone (PG) for GVBD, Akt, and ERK2 activation. To demonstrate that glutamate activation proceeds through the orthosteric site of the mGluR2-LBD, oocytes were pre-incubated with LY341495, a high-affinity mGluR2 antagonist. This inhibitor only blocked glutamate-induced GVBD and had no effect on PG treatment demonstrating the orthosteric binding of glutamate into the mGluR2-LBD of LihIR and LihMET. LihIR and LihMET dead kinase (DK) mutants^[6] did not respond to glutamate either, confirming that tyrosine kinase activity of the chimeras initiates intracellular signaling (Fig. S2).

Insulin receptors are dimers wherein changes of the relative orientation of the TK domain upon TM domain motion regulates catalytic activity and downstream signaling pathways.^[20] To

COMMUNICATION

explore this coupling, we introduced both a single amino acid extension and truncation of the TM domain. Exposure of the truncated version to glutamate had no effect. By contrast, the extended construct was still able to signal through ERK2 but not through Akt. Moreover, this extended mutant was able to phosphorylate JNK (Fig. S3). This modified intracellular signaling pathway confirms that small differences in receptor sequence can result on a pronounced change of signal bias.

Figure 3. LihIR and LihMET kinase activity assay in *Xenopus* oocytes. (A) Oocytes undergo germinal vesicle breakdown (GVBD) in response to outside stimuli that result in an increase of MAPK activity, observable by the formation of a white spot on the brown oocyte pole. (B) Immunoprecipitation (IP) and Western blots (WB, 15 oocytes per condition) show downstream phosphorylation of receptor and effectors only in presence of glutamate and in absence of the orthosteric, competitive antagonist LY341495. Each condition was assayed for GVBD of 20 oocytes. >80% of oocytes that undergo GVBD are considered positive (+). Progesterone (PG) served as positive control.

Development of a Synthetic Photoreceptor

Having achieved the conversion hIR and hMET into glutamate receptors, we next imparted light sensitivity to our protein chimeras. To this end, we chose the photoswitchable orthogonal remotely-tethered ligand (PORTL) approach, which was developed by our laboratories to enable precise photo-control of mGluRs *in vivo*.^[21] This system relies on robust self-labelling protein tags, such as *N*-terminally fused SNAP tags, that covalently react with the benzyl guanine **BGAG₈** (benzylguanine-azobenzene-glutamate).^[16] The structure of this molecule is shown in Fig. 2A and the assembly and function of the synthetic photoreceptor is schematically shown in Fig. 2B. Accordingly, we labelled LihIR and LiMET with **BGAG₈** and illuminated the oocytes with a 365 nm light source. Indeed, we observed all downstream events that were previously recorded after glutamate exposure (Fig. 4).

To confirm the need for covalent receptor labelling, we tested the freely diffusible ligand **AG₁₂** which lacks a benzyl guanine for bioconjugation (Fig S4). Exposure to **AG₁₂** (100 μ M) in the dark, followed by irradiation (365 nm), did not result in activation of either chimera. This is in line with our previous findings with mGluRs where covalent attachment was needed to ensure the high local concentration necessary for successful PORTL photo-control.^[16]

As expected, the LihIR and LihMET dead kinase mutants did not activate following **BGAG₈** labeling and 365 nm illumination (FIG. S4). To demonstrate that glutamate binding to the mGluR2-LBD is a prerequisite for activation of our chimeras, we generated the point mutations S145A and T168A, which are known to abolish orthosteric glutamate-binding in the mGluR2-LBD.^[22] Indeed, these mutants could not be activated with **BGAG₈** (Fig. 4) or with glutamate (Fig. S5). This confirms that orthosteric binding is required to trigger tyrosine kinase activity and downstream signaling cascades.

Figure 4. BGAG₈ labeled LihIR and LihMet are activated by light. 10 *Xenopus* oocytes were used for each GVBD assay and 25 each for IP and WB (in total 60 oocytes per vertical lane). Point mutations S145A and T168A abolish glutamate-binding and serve as negative controls.

Discussion

Using a combination of protein engineering and tethered photopharmacology^[23], we have created two RTKs that contain a ligand-binding domain sensitive to small molecules. Furthermore, we converted these engineered receptors into light-sensitive RTKs. Initial attempts to convert VKRs themselves into photoreceptors had been unsuccessful. Since our PORTL approach to the optical control of mGluR2 worked well^[16, 21, 24] and since the downstream effects of hIR and hMET were much better understood than VKRs, we ultimately settled on a more audacious approach merging two receptors involved in very different signal transduction pathways. Our results confirm that the recombination of modules from vastly different families can lead to functional transmembrane receptors with interesting functional properties.

The optical control of RTK pathways has also been achieved using optogenetic strategies. "Opto-RTKs" have been created by fusing aureochrome LOV domains to various intracellular kinase domains.^[25] The resulting constructs lacked extracellular LBDs and were insensitive to ligands but could be activated with blue light. Spatiotemporal control of RTK signals could also be achieved via light-induced cryptochrome oligomerization.^[26] Our systems, by contrast, rely on chimeric proteins that retain an extracellular LBD and require the covalent attachment of synthetic photoswitches. LihIR and LiMET are minimally modified on their

COMMUNICATION

intracellular domains and presumably retain most of the interactome of their parents (hIR and hMET). They can be conditionally made photosensitive through addition of a synthetic molecule, **BGAG₈**. This allows for another level of control and prevents undesired light-activation after expression of a photoreceptor.

The ability to control RTKs with small molecules that have well-defined pharmacology, such as glutamate and its analogs, opens new perspectives in chemogenetics.^[27] It should be possible, for instance, to engineer RTKs that respond to diffusible ligands that are normally inactive or to tethered ligands that do not effectively activate native receptors before bioconjugation. The tethered photopharmacology described herein should enable the activation of distinct RTK signaling pathways in mammalian cells with higher spatiotemporal precision than conventional pharmacology. Studies in this direction are ongoing in our laboratories and will be reported in due course.

Experimental Section

Experimental Details can be found in the Supporting Information.

Acknowledgements

P.L. and D.T. acknowledge support from the SFB 749 and FOR 1249. P.L. is grateful to the Boehringer Ingelheim Fonds for a travel grant and Prof. Dr. Kai Johnsson for support and advice. J.B. is grateful to a Studienstiftung des deutschen Volkes PhD Fellowship and an EMBO Short Term Fellowship (490-2011). P.L., J.B. and D.T. were supported by the Center for Integrated Protein Science Munich (CIPSM). D.T. acknowledges funding from the European Research Council (Advanced Grant 268795). A.M., C.D. and J.V. were supported by CNRS, INSERM and Université de Lille Nord de France. We thank Prof. Dr. Harald Janovjak (Monash), Prof. Dr. Axel Ullrich and Dr. Robert Torka (MPI Biochemistry Munich) for discussions, advice and support.

Keywords: receptor tyrosine kinase • insulin receptor • met receptor • glutamate • metabotropic glutamate receptor • photopharmacology • synthetic biology • photoswitchable orthogonal remotely-tethered ligand (PORTL)

- [1] B. Alberts, A. Johnson, J. Lewis, M. Raff, K. Roberts, P. Walter, *Molecular Biology of the Cell*, 5. ed., Garland Science, **2007**.
- [2] M. A. Lemmon, J. Schlessinger, *Cell* **2010**, *141*, 1117-1134.
- [3] M. Vanderstraete, N. Gougnard, A. Ahier, M. Morel, J. Vicogne, C. Dissous, *BMC Genomics* **2013**, *14*, 361.
- [4] J. Vicogne, J. P. Pin, V. Lardans, M. Capron, C. Noel, C. Dissous, *Mol Biochem Parasitol* **2003**, *126*, 51-62.
- [5] A. Ahier, P. Rondard, N. Gougnard, N. Khayath, S. Huang, J. Trolet, D. J. Donoghue, M. Gauthier, J. P. Pin, C. Dissous, *PLoS One* **2009**, *4*, e5651.
- [6] M. Vanderstraete, N. Gougnard, K. Cailliau, M. Morel, S. Hahnel, S. Leutner, S. Beckmann, C. G. Greveling, C. Dissous, *PLoS Pathog* **2014**, *10*, e1004138.
- [7] N. Gougnard, F. Cherrier, E. Brito-Fravallo, A. Pain, N. M. Zmarlak, K. Cailliau, C. Geneve, K. D. Vernick, C. Dissous, C. Mitri, *Sci Rep* **2019**, *9*, 3615.
- [8] J. P. Pin, T. Galvez, L. Prezeau, *Pharmacol Ther* **2003**, *98*, 325-354.
- [9] C. B. Felder, R. C. Gaul, A. Y. Lee, H. P. Merkle, W. Sadec, *AAPS PharmSci* **1999**, *1*, E2.
- [10] a) L. He, Y. Zhang, G. Ma, P. Tan, Z. Li, S. Zang, X. Wu, J. Jing, S. Fang, L. Zhou, Y. Wang, Y. Huang, P. G. Hogan, G. Han, Y. Zhou, *Elife* **2015**, *4*; b) T. Kyung, S. Lee, J. E. Kim, T. Cho, H. Park, Y. M. Jeong, D. Kim, A. Shin, S. Kim, J. Baek, J. Kim, N. Y. Kim, D. Woo, S. Chae, C. H. Kim, H. S. Shin, Y. M. Han, D. Kim, W. D. Heo, *Nat Biotechnol* **2015**, *33*, 1092-1096; c) C. J. Magnus, P. H. Lee, D. Atasoy, H. H. Su, L. L. Looger, S. M. Sternson, *Science* **2011**, *333*, 1292-1296.
- [11] H. Riedel, T. J. Dull, J. Schlessinger, A. Ullrich, *Nature* **1986**, *324*, 68-70.
- [12] J. M. Kim, J. Hwa, P. Garriga, P. J. Reeves, U. L. RajBhandary, H. G. Khorana, *Biochemistry* **2005**, *44*, 2284-2292.
- [13] aM. A. Morgan, A. Schambach, *Front Immunol* **2018**, *9*, 2493; bK. T. Roybal, W. A. Lim, *Annu Rev Immunol* **2017**, *35*, 229-253.
- [14] L. Morsut, K. T. Roybal, X. Xiong, R. M. Gordley, S. M. Coyle, M. Thomson, W. A. Lim, *Cell* **2016**, *164*, 780-791.
- [15] L. Liu, Y. Liu, G. Zhang, Y. Ge, X. Fan, F. Lin, J. Wang, H. Zheng, X. Xie, X. Zeng, P. R. Chen, *Biochemistry* **2018**, *57*, 446-450.
- [16] J. Broichhagen, A. Damijonaitis, J. Levitz, K. R. Sokol, P. Leippe, D. Konrad, E. Y. Isacoff, D. Trauner, *ACS Cent Sci* **2015**, *1*, 383-393.
- [17] E. Doumazane, P. Scholler, J. M. Zwier, E. Trinquet, P. Rondard, J. P. Pin, *Faseb J* **2011**, *25*, 66-77.
- [18] L. Xue, I. A. Karpenko, J. Hiblot, K. Johnsson, *Nat Chem Biol* **2015**, *11*, 917-923.
- [19] N. Gougnard, M. Vanderstraete, K. Cailliau, A. Lescuyer, E. Browaeys, C. Dissous, *Exp Parasitol* **2012**, *132*, 32-39.
- [20] a) I. N. Maruyama, *Bioessays* **2015**, *37*, 959-967; b) J. Lee, M. Miyazaki, G. R. Romeo, S. E. Shoelson, *J Biol Chem* **2014**, *289*, 19769-19777; c) J. M. Kavran, J. M. McCabe, P. O. Byrne, M. K. Connacher, Z. Wang, A. Ramek, S. Sarabipour, Y. Shan, D. E. Shaw, K. Hristova, P. A. Cole, D. J. Leahy, *Elife* **2014**, *3*.
- [21] a) J. Levitz, J. Broichhagen, P. Leippe, D. Konrad, D. Trauner, E. Y. Isacoff, *Proc Natl Acad Sci U S A* **2017**, *114*, E3546-E3554; b) A. Acosta-Ruiz, V. A. Gutzeit, M. J. Skelly, S. Meadows, J. Lee, A. G. Orr, C. Liston, K. E. Pleil, J. Broichhagen, J. Levitz, *Neuron* **2019**, <https://doi.org/10.1016/j.neuron.2019.10.036>.
- [22] P. Malherbe, F. Knoflach, C. Broger, S. Ohresser, C. Kratzeisen, G. Adam, H. Stadler, J. A. Kemp, V. Mutel, *Mol Pharmacol* **2001**, *60*, 944-954.
- [23] P. Leippe, J. Koehler Leman, D. Trauner, *Biochemistry* **2017**, *56*, 5214-5220.
- [24] a) M. H. Berry, A. Holt, J. Levitz, J. Broichhagen, B. M. Gaub, M. Visel, C. Stanley, K. Aghi, Y. J. Kim, K. Cao, R. H. Kramer, D. Trauner, J. Flannery, E. Y. Isacoff, *Nat Commun* **2017**, *8*, 1862; b) P. C. Donthamsetti, J. Broichhagen, V. Vyklícky, C. Stanley, Z. Fu, M. Visel, J. L. Levitz, J. A. Javitch, D. Trauner, E. Y. Isacoff, *J Am Chem Soc* **2019**, *141*, 11522-11530.
- [25] a) M. Grusch, K. Schelch, R. Riedler, E. Reichhart, C. Differ, W. Berger, A. Ingles-Prieto, H. Janovjak, *EMBO J* **2014**, *33*, 1713-1726; b) N. Kim, J. M. Kim, M. Lee, C. Y. Kim, K. Y. Chang, W. D. Heo, *Chemistry & biology* **2014**, *21*, 903-912.
- [26] E. Reichhart, A. Ingles-Prieto, A. M. Tichy, C. McKenzie, H. Janovjak, *Angew Chem Int Ed Engl* **2016**, *55*, 6339-6342.
- [27] a) B. L. Roth, *Curr Opin Struct Biol* **2019**, *57*, 9-16; b) S. Mondoloni, R. Durand-de Cuttoli, A. Mouro, *Trends Pharmacol Sci* **2019**, *40*, 696-710.

COMMUNICATION

Entry for the Table of Contents

COMMUNICATION

Using a combination of molecular cloning and chemical synthesis, the human insulin receptor has been converted into a glutamate and a photoreceptor. The approach is also applicable to the hepatocyte growth factor receptor.

Philipp Leippe, Johannes Broichhagen, Katia Cailliau, Alexandra Mougel, Marion Morel, Colette Dissous, Dirk Trauner* and Jerome Vicogne*

Page No. – Page No.

Transformation of Receptor Tyrosine Kinases into Glutamate Receptors and Photoreceptors